The therapeutic approaches of renal recovery after relief of the unilateral ureteral obstruction: A comprehensive review

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 273

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-23-11_001

تاریخ نمایه سازی: 19 دی 1399

Abstract:

Unilateral ureteral obstruction (UUO) as a clinical disorder can cause renal damage. The permanent injury occurs if the obstruction is not relieved. Renal injury can be reversed with UUO removal (RUUO). RUUO attenuates the renal hemodynamic and functional impairment and decreases the renal fibrosis and apoptosis. Nevertheless, kidney injury may continue after RUUO, and synchronous medication therapy seems necessary. However, UUO and post-RUUO periods are also important in final renal recovery. To date, various therapeutic strategies have been applied to develop renal recoverability after RUUO. In animal studies, the effect of some pharmacological agents such as mesenchymal stem cells, anti-inflammation drugs, L-arginine, bone morphogenetic protein-7, epidermal growth factor, allopurinol, renin-angiotensin system antagonists, and endothelin A/B receptor blocker were surveyed in RUUO model. Also, post-RUUO renal recoverability has been studied in human researches. In these studies, the effective strategies have focused on surgery for RUUO creation via urethrotomy, urethroplasty, stent balloon dilatation, and stenting. Accordingly, in this review, we focused on the therapeutic procedure of renal recovery after the RUUO situation in human and animal studies.

Keywords:

Animal Human Recovery Relief Therapeutic procedure Unilateral Ureteral , Obstruction

Authors

Ayat Kaeidi

Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Maryam Maleki

Department of Physiology, Ilam University of Medical Sciences, Ilam, Iran

Ali Shamsizadeh

Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Iman Fatemi

Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran

Elham Hakimizadeh

Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Jalal Hassanshahi

Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1. Klahr S, Morrissey J. Comparative effects of ACE inhibition ...
  • 2. Kaeidi A, Taghipour Z, Allahtavakoli M, Fatemi I, Hakimizadeh ...
  • 3. Warady BA, Chadha V. Chronic kidney disease in children: ...
  • 4. Singh I, Strandhoy J, Assimos D. Pathophysiology of urinary ...
  • 5. Kaeidi A, Sahamsizadeh A, Allahtavakoli M, Fatemi I, Rahmani ...
  • 6. Kluth DC, Erwig L-P, Rees AJ. Multiple facets of ...
  • 7. Misseri R, Meldrum DR, Dagher P, Hile K, Rink ...
  • 8. Rastaldi MP. Epithelial-mesenchymal transition and its implications for the ...
  • 9. Kaeidi A, Rasoulian B, Hajializadeh Z, Pourkhodadad S, Rezaei ...
  • 10. Rasoulian B, Kaeidi A, Pourkhodadad S, Dezfoulian O, Rezaei ...
  • 11. Rasoulian B, Kaeidi A, Rezaei M, Hajializadeh Z. Cellular ...
  • 12. Hassanshahi J, Maleki M, Nematbakhsh M. Renin-angiotensin system and ...
  • 13. Khalaf IM, Shokeir AA, El-Gyoushi FI, Amr HS, Amin ...
  • 14. Albani JM, Desai MM, Gill IS, Streem SB. Repair ...
  • 15. Hassanshahi J, Maleki M, Nematbakhsh M. Renal blood flow ...
  • 16. Cochrane AL, Kett MM, Samuel CS, Campanale NV, Anderson ...
  • 17. Ito K, Chen J, El Chaar M, Stern JM, ...
  • 18. Li C, Wang W, Knepper MA, Nielsen S, Frøkiær ...
  • 19. Li C, Wang W, Kwon T-H, Knepper MA, Nielsen ...
  • 20. Chevalier RL, Kim A, Thornhill BA, Wolstenholme JT. Recovery ...
  • 21. Chevalier RL, Thornhill BA, Chang AY. Unilateral ureteral obstruction ...
  • 22. Chan W, Krieg Jr RJ, Ward K, Santos Jr ...
  • 23. Roth KS, Carter Jr WH, Chan JC. Obstructive nephropathy ...
  • 24. Ito K, Chen J, Seshan SV, Khodadadian JJ, Gallagher ...
  • 25. Downey P, Tolley D, Johnston S, Young M. Ischemia–Reperfusion ...
  • 26. Morrissey J, Hruska K, Guo G, Wang S, Chen ...
  • 27. Hesketh EE, Vernon MA, Ding P, Clay S, Borthwick ...
  • 28. Chevalier RL, Thornhill BA, Chang AY, Cachat F, Lackey ...
  • 29. Soliman SA, Shokeir AA, Mosbah A, Abol-Enein H, Barakat ...
  • 30. Koo JW, Kim Y, Rozen S, Mauer M. Enalapril ...
  • 31. Chaabane W, Praddaude F, Buleon M, Jaafar A, Vallet ...
  • 32. Tapmeier T, Brown K, Tang Z, Sacks S, Sheerin ...
  • 33. Puri TS, Shakaib MI, Chang A, Mathew L, Olayinka ...
  • 34. Ma H, Saenko M, Opuko A, Togawa A, Soda ...
  • 35. Liu Y, Sun J, Miao L, Ji L, Luo ...
  • 36. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells ...
  • 37. Rookmaaker MB, Verhaar M, Van Zonneveld A, Rabelink TJ. ...
  • 38. Menè P, Polci R, Festuccia F. Mechanisms of repair ...
  • 39. Thornhill B, Forbes M, Marcinko E, Chevalier R. Glomerulotubular ...
  • 40. Duffield JS. The inflammatory macrophage: a story of Jekyll ...
  • 41. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism ...
  • 42. Sun DF, Fujigaki Y, Fujimoto T, Goto T, Yonemura ...
  • 43. Shi Y, Pedersen M, Li C, Wen JG, Thomsen ...
  • 44. Shokeir AA, Shoma AM, Abubieh EA, Nasser MA, Eassa ...
  • 45. Bai Z-m, Deng X-d, Li J-d, Li D-h, Cao ...
  • 46. Semedo P, Correa‐Costa M, Cenedeze MA, Malheiros DMAC, dos ...
  • 47. Sweeney P, Young L, Fitzpatrick J. An autoradiographic study ...
  • 48. Hammad F, Lubbad L. The effect of diclofenac sodium ...
  • 49. Vonkeman HE, van de Laar MA, editors. Nonsteroidal anti-inflammatory ...
  • 50. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy ...
  • 51. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel ...
  • 52. Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer ...
  • 53. Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer ...
  • 54. Böttinger EP, editor TGF-β in renal injury and disease. ...
  • 55. Miyazono K, Kusanagi K, Inoue H. Divergence and convergence ...
  • 56. El Chaar M, Chen J, Seshan SV, Jha S, ...
  • 57. Sinik Z, Turan T, Demir S, Yilmaz U, Sert ...
  • 58. Hvistendahl JJ, Pedersen TS, Djurhuus JC, Pedersen EB, Frøkiær ...
  • 59. Manucha W, Carrizo L, Ruete C, Molina H, Vallés ...
  • 60. Kellner D, Chen J, Richardson I, Seshan SV, el ...
  • 61. Manucha W, Oliveros L, Carrizo L, Seltzer A, Vallés ...
  • 62. Hassanshahi J, Nematbakhsh M. The role of Mas receptor ...
  • 63. Eiam‐ong S, Udom J, Sueblinvong T, EIAM‐ONG S. Apoptosis ...
  • 64. Chen CO, Park MH, Forbes MS, Thornhill BA, Kiley ...
  • 65. Gonçalves RG, Biato MA, Colosimo RD, Martinusso CA, Pecly ...
  • 66. Hammad FT, Lubbad L. The effect of aliskiren on ...
  • 67. Hammad FT, Wheatley AM, Davis G. Long-term renal effects ...
  • 68. Peterson AC, Webster GD. Management of urethral stricture disease: ...
  • 69. Kim M, Song G, Park SH, Sohn M, Song ...
  • 70. Andrich D, Mundy A. Urethral strictures and their surgical ...
  • 71. Deng GY, Sun JJ, Wang P, Mo JC. Renal ...
  • 72. Tavukçu HH, Tinay İ, Tarcan T. To save or ...
  • 73. Davari HR, Haghighi M, Shahi Z, HASSANZAD AM. Improvement ...
  • 74. Shokeir A, Provoost A, Nijman R. Recoverability of renal ...
  • 75. Armatys SA, Mellon MJ, Beck SD, Koch MO, Foster ...
  • نمایش کامل مراجع